The Changing Role of Topical Therapies in Acne Treatment
As the challenge of antimicrobial resistance continues to grow, fixed-dose combination therapies appear to be the future of treatment of mild to moderate acne.
Acne
ACNE
FEATURE ARTICLE
LATEST NEWS
Hidradenitis Suppurativa Carries Heavy Comorbidity Burden
There is a substantial burden, unawareness, and undertreatment of several systemic comorbidities—particularly cardiovascular and psychiatric—in patients with HS.
Isotretinoin Does Not Increase Liver Enzyme Elevations in Patients With Severe Acne
Acne patients receiving isotretinoin may not need continued testing when experiencing low-grade liver enzyme abnormalities, as most mild elevations do not worsen.
High Prevalence of Body Dysmorphic Disorder Observed in Patients With Acne
A high prevalence of body dysmorphic disorder (BDD) was observed in patients with acne vulgaris at various dermatology centers in Spain, according to study data published in the Journal of the European Academy of Dermatology and Venereology. Investigators conducted a cross-sectional study at 11 dermatology clinics in Spain. The study enrolled patients age 16 to…
Aklief Cream Approved for Acne Vulgaris
The Food and Drug Administration (FDA) has approved Aklief Cream 0.005% (trifarotene; Galderma) for the topical treatment of acne vulgaris in patients 9 years of age and older.
Antibiotic Resistance, Biotypes, Phylotypes in Clinical C acnes Isolates from Facial Acne
Degrees of acne severity reflect different biotype and phylotype distributions.
Inflammation and Dyslipidemia in Acne Vulgaris: Serum YKL40 Correlations
Serum YKL-40 level was significantly elevated in patients with acne, suggesting that it may have a role in acne pathogenesis as well as provide a link between the inflammation and dyslipidemia seen in these patients, a novel study finds.
Opioid-Naïve Patients With Hidradenitis Suppurativa Have Increased Risk of Long-Term Opioid Use
Researchers identified a greater than twofold crude increase in the 1-year incidence of long-term opioid use among patients with HS compared with controls.
Review of Sarecycline Effects on Acne Vulgaris: Results From Two Phase 3 Trials
Significant reduction in inflammatory lesions was seen at week 12 at 1.5 mg/kg/day of sarecycline, with statistically significant improvement seen as early as week 3.
Aczone Gel 7.5% Approved to Treat Acne in Younger Patients
The Food and Drug Administration (FDA) has approved Aczone (dapsone; Almirall) Gel 7.5% for the topical treatment of acne vulgaris in patients aged ≥9 years. Previously, the treatment had been indicated for patients 12 years of age and older.
30% Azelaic Acid Peel Reduces Sebum Secretion, Lesions in Women With Facial Acne
Investigators sought to assess the efficacy of a 30% azelaic acid peel on acne lesions.
Want to read more?
Please login or register first to view this content.
Next post in Acne
